Two technologies, two commercial forms — a strategy review for one research group
A commercial strategy review commissioned by a UK university research group with two adjacent thermal-energy technologies. The review delivered separate commercialisation pathways — spinout for the standalone technology, licensing or integration for the subsystem — and the analytical framework that distinguished the two.
The starting position
A UK university research group approached the engagement with two technologies developed in parallel by the same lead researcher. Both addressed adjacent problems in thermal energy management. Both had reached a credible technical readiness level. Both had a plausible commercial future. The research group needed to know how to commercialise them.
The institutional instinct, faced with two credible technologies from one group, is to commercialise them together — usually as the joint IP base of a single new spinout. That instinct has obvious appeal: it concentrates value, it tells one story to investors, and it lets a single founding team carry both pieces of work. But it is rarely the right answer. Adjacent technologies can have radically different commercial forms even when their technical roots are shared, and choosing the wrong form for either is the kind of mistake that wastes years of research investment.
What the research group needed was an external commercial assessment of both technologies on the same terms — to surface the commercial profile of each on its own merits, and to recommend the form, route, and sequencing for each independently.
What we did
The engagement was scoped and contracted as a paid commercial strategy review across both technologies. The work was anchored on three connected questions for each technology: what commercial form fits, what is the route to market, and what is the realistic technical roadmap to deployment readiness.
Technology and value-proposition assessment. We characterised each technology against the same framework — what it is, what it solves, where it differentiates, and what its technical readiness level is against the development roadmap that would take it to deployment. The two technologies looked similar at a research-group level. Assessed against the framework, they diverged immediately.
Market analysis across two adjacent sectors. The two technologies sat in adjacent but distinct industrial sectors with overlapping customers, different procurement cycles, different regulatory drivers, and different competitive landscapes. We analysed both sectors separately and made the differences explicit — what looked like a single market opportunity at the research-group level was two markets when assessed commercially.
Competitive landscape mapping. We identified the credible incumbents in each adjacent product category and mapped how each technology positioned against them. The standalone technology had clear differentiation against the named incumbents. The subsystem technology sat alongside, not against, the equivalent incumbents — it was an enhancement to their products rather than a replacement for them. That distinction shaped the commercial form recommendation directly.
Technical roadmap and gap analysis for each. We produced a development roadmap and gap analysis for each technology separately, with the work-package structure and partnership requirements that would close the gaps in each case. The technologies sat at different TRLs and required different development sequencing — they could not be advanced together on a single roadmap.
Commercialisation route options. For each technology, we set out the commercialisation route options — spinout, licensing, joint venture, integration with an established partner — and recommended the form best fitted to that technology’s profile. Then we set out the relationship between the two recommendations, since the research group would need to execute both pathways in coordination if they were going to do justice to either.
The commercial move
The most consequential analytical move in the engagement was the recognition that the two technologies, despite their shared technical roots, were not the same kind of commercial proposition.
The standalone technology was a product. It could be sold as a discrete unit. It could be specified, certified, and deployed without a host system. It had clear differentiation against named incumbents in its product category. Its market — multiple adjacent applications across residential, commercial, and industrial settings — was broad enough to support a focused spinout with multiple licensing routes downstream. The recommendation for this technology was a dedicated spinout, with the IP held by the new company and licensing as a secondary revenue stream.
The subsystem technology was a feature. It enhanced the performance of an existing class of equipment but could not be sold to end-users on its own — adoption required integration into a host system manufactured by an established player. The market was narrower, dominated by a small number of incumbent equipment manufacturers, and the commercial unit of value was a license or co-development agreement with one of those incumbents rather than a direct sale to an end-user. The recommendation for this technology was licensing or integration with an established player, not a separate spinout.
Two consequences follow from that pair of recommendations.
Trying to build two spinouts where the evidence supports one is the most expensive form of optimism in deep-tech commercialisation. It splits the founding team’s attention, raises the cost of fundraising, and leaves the weaker of the two propositions absorbing capital that should be going into the stronger. The discipline is to recognise — early — which technology can carry a company and which technology should be commercialised through someone else’s.
The two pathways need to be coordinated. The subsystem technology’s licensing programme will produce conversations with established equipment manufacturers — and those manufacturers are exactly the partner ecosystem the standalone-technology spinout will eventually need for its industrial-application licensing. Sequenced well, the subsystem licensing work becomes the relationship-building substrate for the spinout’s downstream licensing programme, and the value of doing both engagements together compounds.
What the engagement produced
- A parallel technology and value-proposition assessment for both technologies, against a common analytical framework.
- A market analysis covering both adjacent industrial sectors, with the differences in procurement cycle, regulatory driver, and competitive landscape made explicit.
- A competitive landscape mapping for each technology, with named incumbents in each adjacent product category and the positioning of each technology against them.
- Technical roadmaps and gap analyses for each technology — separately structured, since the two could not be developed together on a single roadmap.
- Commercialisation route options for each technology, with a specific form recommended for each: a dedicated spinout for the standalone technology, licensing or integration with an established partner for the subsystem technology.
- A coordination framework specifying how the two pathways should be sequenced — so that the subsystem licensing programme builds the relationships the spinout will eventually need for its downstream licensing.
- A risk register covering both technical and commercial risks for each technology, with mitigation framing.
- A future development plan with funding routes mapped to the development stage of each technology.
Why it matters
The general-purpose observation is that adjacent technical roots can produce radically different commercial outcomes.
Research groups are typically more confident about the science underpinning their work than about the commercial form their work should take. That is the right way round — research groups are not commercialisation specialists, and they should not be expected to be. But it means that the question of commercial form, when it is finally asked, is often answered by institutional reflex rather than by analysis. The reflex with two adjacent technologies is to commercialise them together. The reflex is wrong often enough that asking the question with discipline pays for itself many times over.
The discipline is recognising which of two credible technologies is a product, which is a feature, and treating each accordingly. A product can carry a spinout. A feature cannot — it has to be commercialised through someone else’s product. Confusing the two is one of the most common failure modes in early-stage deep-tech commercialisation, and it is a failure mode that has nothing to do with the underlying science being good or not. The science is usually fine. The commercial form is what gets it wrong.
For a research group with credible IP in adjacent areas, the work of distinguishing product from feature is not optional. It is the gating analytical step before any commercialisation pathway can be confidently chosen.
A note on status
The engagement is complete and the strategy review is delivered. Subsequent commercialisation activity remains commercially confidential. This case study describes Hatch Oxford’s methodology at the level it can be discussed publicly. The client, the technologies, the application sectors, the specific findings, and any counterparties are not identified.
